Imaging Immune Activation in HIV by PET-MR

Part of paid clinical trials in San Francisco, California.

Sponsor
CellSight Technologies, Inc.
Study ID
NCT03684655
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) — DRUG
    \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.

Study Details

This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.

Key Dates

Start date
Sep 21, 2018
Status verified
Oct 2024
Primary completion
Oct 1, 2025
Completion
Nov 1, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: [18F]F-AraG
    radiofluorinated imaging agent, \[18F\]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) Trade name: VisAcT

Primary Outcome Measure

Anatomical distribution of [18F]F-AraG [ Time Frame: 1-4 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94110
Timothy J Henrich, MD
[email protected]
415-206-5518
Timothy J Henrich, MD (PRINCIPAL_INVESTIGATOR)
Henry F Vanbrocklin, PhD (SUB_INVESTIGATOR)
Steven J Deeks, MD (SUB_INVESTIGATOR)
Robert Flavell, MD (SUB_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
HIV
By specialty
Infectious disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies